Patient characteristics
| Variable . | RD/1AG-MM-GVH (n = 327) . | 8/8 MUD (n = 452) . | P . |
|---|---|---|---|
| Median age at transplantation, y (range) | 45 (16-69) | 48 (16-68) | .043 |
| Recipient sex, n (%) | |||
| Male | 184 (56%) | 267 (59%) | .434 |
| Female | 143 (44%) | 185 (41%) | |
| Sex combination of donors and recipients, n (%) | |||
| Female to male | 91 (28%) | 73 (16%) | < .001 |
| Other combinations | 236 (72%) | 379 (84%) | |
| Performance status, n (%) | |||
| 0/1 | 298 (91%) | 415 (92%) | .736 |
| 2/3/4 | 29 (9%) | 37 (8%) | |
| Disease, n (%) | |||
| AML | 167 (51%) | 249 (55%) | .512 |
| ALL | 90 (28%) | 107 (24%) | |
| CML | 19 (6%) | 21 (5%) | |
| MDS | 51 (16%) | 75 (17%) | |
| Duration from diagnosis to transplantation, n (%) | |||
| < 6 mo | 124 (38%) | 102 (23%) | < .001 |
| ≥ 6 mo | 191 (58%) | 350 (77%) | |
| Unknown | 12 (4%) | 0 (0%) | |
| Disease risk, n (%) | |||
| Standard | 175 (54%) | 317 (70%) | < .001 |
| High | 133 (41%) | 129 (29%) | |
| Unknown | 19 (6%) | 6 (1%) | |
| Source of stem cells, n (%) | |||
| BM | 142 (43%) | 452 (100%) | < .001 |
| Peripheral blood | 185 (57%) | ||
| HLA compatibility in the HVG direction, n (%)* | |||
| Matched | 36 (11%) | 452 (100%) | < .001 |
| 1-antigen mismatch | 218 (67%) | ||
| 2-antigen mismatch | 65 (20%) | ||
| 3-antigen mismatch | 8 (2%) | ||
| HLA compatibility in the GVH direction, n (%)* | |||
| Matched | 0 (0%) | 452 (100%) | < .001 |
| 1-allele mismatch | 111 (34%) | ||
| 2-allele mismatch | 36 (11%) | ||
| 3-allele mismatch | 1 (0%) | ||
| Uncertain/missing | 179 (55%) | ||
| Conditioning regimen, n (%) | |||
| Myeloablative | 243 (74%) | 338 (75%) | .883 |
| Reduced-intensity | 84 (26%) | 114 (25%) | |
| GVHD prophylaxis, n (%) | |||
| Cyclosporine-based | 113 (35%) | 108 (24%) | 0.004 |
| Tacrolimus-based | 209 (64%) | 338 (75%) | |
| Others | 5 (2%) | 6 (1%) | |
| Use of ATG/alemtuzumab, n (%) | |||
| Yes | 33 (10%) | 13 (3%) | < .001 |
| No | 294 (90%) | 439 (97%) | |
| Median follow-up of survivors, mo (range) | 36.2 (3.0-95.7) | 13.5 (1.7-62.8) | < .001 |
| Variable . | RD/1AG-MM-GVH (n = 327) . | 8/8 MUD (n = 452) . | P . |
|---|---|---|---|
| Median age at transplantation, y (range) | 45 (16-69) | 48 (16-68) | .043 |
| Recipient sex, n (%) | |||
| Male | 184 (56%) | 267 (59%) | .434 |
| Female | 143 (44%) | 185 (41%) | |
| Sex combination of donors and recipients, n (%) | |||
| Female to male | 91 (28%) | 73 (16%) | < .001 |
| Other combinations | 236 (72%) | 379 (84%) | |
| Performance status, n (%) | |||
| 0/1 | 298 (91%) | 415 (92%) | .736 |
| 2/3/4 | 29 (9%) | 37 (8%) | |
| Disease, n (%) | |||
| AML | 167 (51%) | 249 (55%) | .512 |
| ALL | 90 (28%) | 107 (24%) | |
| CML | 19 (6%) | 21 (5%) | |
| MDS | 51 (16%) | 75 (17%) | |
| Duration from diagnosis to transplantation, n (%) | |||
| < 6 mo | 124 (38%) | 102 (23%) | < .001 |
| ≥ 6 mo | 191 (58%) | 350 (77%) | |
| Unknown | 12 (4%) | 0 (0%) | |
| Disease risk, n (%) | |||
| Standard | 175 (54%) | 317 (70%) | < .001 |
| High | 133 (41%) | 129 (29%) | |
| Unknown | 19 (6%) | 6 (1%) | |
| Source of stem cells, n (%) | |||
| BM | 142 (43%) | 452 (100%) | < .001 |
| Peripheral blood | 185 (57%) | ||
| HLA compatibility in the HVG direction, n (%)* | |||
| Matched | 36 (11%) | 452 (100%) | < .001 |
| 1-antigen mismatch | 218 (67%) | ||
| 2-antigen mismatch | 65 (20%) | ||
| 3-antigen mismatch | 8 (2%) | ||
| HLA compatibility in the GVH direction, n (%)* | |||
| Matched | 0 (0%) | 452 (100%) | < .001 |
| 1-allele mismatch | 111 (34%) | ||
| 2-allele mismatch | 36 (11%) | ||
| 3-allele mismatch | 1 (0%) | ||
| Uncertain/missing | 179 (55%) | ||
| Conditioning regimen, n (%) | |||
| Myeloablative | 243 (74%) | 338 (75%) | .883 |
| Reduced-intensity | 84 (26%) | 114 (25%) | |
| GVHD prophylaxis, n (%) | |||
| Cyclosporine-based | 113 (35%) | 108 (24%) | 0.004 |
| Tacrolimus-based | 209 (64%) | 338 (75%) | |
| Others | 5 (2%) | 6 (1%) | |
| Use of ATG/alemtuzumab, n (%) | |||
| Yes | 33 (10%) | 13 (3%) | < .001 |
| No | 294 (90%) | 439 (97%) | |
| Median follow-up of survivors, mo (range) | 36.2 (3.0-95.7) | 13.5 (1.7-62.8) | < .001 |
HLA compatibility was defined according to the HLA-A, HLA-B, and HLA-DR loci.